Digital companions for oncology therapeutics

Alacrity Care’s CloudOnc® platform enables the next generation of precision technologies for toxicity prediction and personalized management.

 
Visual1.png

We develop end-to-end solutions that address key AE management needs

Our digital biomarkers are unlocking the real-world potential of AI through best-in-class real world data collection and a robust infrastructure of clinical support.

 
Visual2.png
 

Solution

Integrated data collection in the patient’s home

We leverage a broad spectrum of wearables, spot assessment tools, and point-of-care blood analysis devices to design a monitoring approach focused on specific AE detection needs.

 
Visual3_2.png

Applying the potential of AI in real-world clinical models

Our analytics enable the detection of SAEs 6-12 hours ahead of the current treatment paradigm, and detection of low-grade AEs >24hrs ahead of the current treatment paradigm. Our oncology digital biomarker enables the majority of AEs to be detected and managed through fully digital workflows.

Visual4.png
 

Our infrastructure difference

 
noun_Stethoscope_949721.png
 

 Clinical support

The 24/7 monitoring backend of licensed oncology practitioners enables acute event escalation and seamless integration into a multitude of clinical settings.

 
 
noun_Friend_2531936.png
 

Patient services

Patient navigators remotely onboard and support patients 1:1 through the treatment journey. Our service approach creates unparalleled patient compliance.

Poised to bring the first digital companions into market in 2023